Development and Mechanism of Small Activating RNA Targeting CEBPA, a Novel Therapeutic in Clinical Trials for Liver Cancer

Molecular Therapy

Volumn 25, Issue 12, 2017, Pages 2705-2714

  Voutila, Jon ^a   Reebye, Vikash ^b   Roberts, Thomas C ^c   Protopapa, Pantelitsa ^a   Andrikakou, Pinelopi ^b   Blakey, David C ^a   Habib, Robert ^a   Huber, Hans ^d   Saetrom, Pal ^e   Rossi, John J ^f   Habib, Nagy A ^b  

^a MiNA Therapeutics Ltd   (United Kingdom)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

^c SCRIPPS RESEARCH INSTITUTE   (United States)

^d BioTD Strategies   (United States)

^e NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Norway)

^f CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

Author keywords

C EBP; CEBPA; HCC; hepatocellular carcinoma; liver cancer; RNA activation; saRNA; small RNA

Indexed keywords

ANTINEOPLASTIC AGENT; ARGONAUTE 2 PROTEIN; CCAAT ENHANCER BINDING PROTEIN ALPHA; MESSENGER RNA; SMALL ACTIVATING RNA; UNCLASSIFIED DRUG; CCAAT ENHANCER BINDING PROTEIN; CEBPA PROTEIN, HUMAN; DOUBLE STRANDED RNA;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CEBPA GENE; CHEMICAL MODIFICATION; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; DRUG DETERMINATION; DRUG TARGETING; GENE IDENTIFICATION; GENE LOCATION; GENE LOCUS; GENETIC TRANSCRIPTION; HEPATOCELLULAR CARCINOMA CELL LINE; HUMAN; HUMAN CELL; INNATE IMMUNITY; LIVER CANCER; PROTEIN TARGETING; RNA SEQUENCE; TUMOR GENE; UPREGULATION; BIOLOGY; CELL CULTURE; GENETICS; HEP-G2 CELL LINE; LIVER TUMOR; PROCEDURES; RNA INTERFERENCE;

CCAAT-ENHANCER-BINDING PROTEINS; CELLS, CULTURED; COMPUTATIONAL BIOLOGY; HEP G2 CELLS; HUMANS; LIVER NEOPLASMS; RNA INTERFERENCE; RNA, DOUBLE-STRANDED; RNA, MESSENGER;

EID: 85028675354     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1016/j.ymthe.2017.07.018     Document Type: Article

References (35)

1. Li, L.C., Okino, S.T., Zhao, H., Pookot, D., Place, R.F., Urakami, S., Enokida, H., Dahiya, R., Small dsRNAs induce transcriptional activation in human cells. Proc. Natl. Acad. Sci. USA 103 (2006), 17337–17342.
2. Janowski, B.A., Younger, S.T., Hardy, D.B., Ram, R., Huffman, K.E., Corey, D.R., Activating gene expression in mammalian cells with promoter-targeted duplex RNAs. Nat. Chem. Biol. 3 (2007), 166–173.
3. Turunen, M.P., Lehtola, T., Heinonen, S.E., Assefa, G.S., Korpisalo, P., Girnary, R., Glass, C.K., Väisänen, S., Ylä-Herttuala, S., Efficient regulation of VEGF expression by promoter-targeted lentiviral shRNAs based on epigenetic mechanism: a novel example of epigenetherapy. Circ. Res. 105 (2009), 604–609.
4. Chu, Y., Yue, X., Younger, S.T., Janowski, B.A., Corey, D.R., Involvement of argonaute proteins in gene silencing and activation by RNAs complementary to a non-coding transcript at the progesterone receptor promoter. Nucleic Acids Res. 38 (2010), 7736–7748.
5. Huang, V., Qin, Y., Wang, J., Wang, X., Place, R.F., Lin, G., Lue, T.F., Li, L.C., RNAa is conserved in mammalian cells. PLoS ONE, 5, 2010, e8848.
6. Wang, J., Place, R.F., Huang, V., Wang, X., Noonan, E.J., Magyar, C.E., Huang, J., Li, L.C., Prognostic value and function of KLF4 in prostate cancer: RNAa and vector-mediated overexpression identify KLF4 as an inhibitor of tumor cell growth and migration. Cancer Res. 70 (2010), 10182–10191.
7. Voutila, J., Sætrom, P., Mintz, P., Sun, G., Alluin, J., Rossi, J.J., Habib, N.A., Kasahara, N., Gene expression profile changes after short-activating RNA-mediated induction of endogenous pluripotency factors in human mesenchymal stem cells. Mol. Ther. Nucleic Acids, 1, 2012, e35.
8. Wang, X., Wang, J., Huang, V., Place, R.F., Li, L.C., Induction of NANOG expression by targeting promoter sequence with small activating RNA antagonizes retinoic acid-induced differentiation. Biochem. J. 443 (2012), 821–828.
9. Wang, T., Li, M., Yuan, H., Zhan, Y., Xu, H., Wang, S., Yang, W., Liu, J., Ye, Z., Li, L.C., saRNA guided iNOS up-regulation improves erectile function of diabetic rats. J. Urol. 190 (2013), 790–798.
10. Reebye, V., Saetrom, P., Mintz, P.J., Rossi, J.J., Kasahara, N., Nteliopoulos, G., Nicholls, J., Haoudi, A., Gordon, M., Habib, N.A., A short-activating RNA oligonucleotide targeting the islet β-cell transcriptional factor MafA in CD34(+) cells. Mol. Ther. Nucleic Acids, 2, 2013, e97.
11. Reebye, V., Sætrom, P., Mintz, P.J., Huang, K.W., Swiderski, P., Peng, L., Liu, C., Liu, X., Lindkaer-Jensen, S., Zacharoulis, D., et al. Novel RNA oligonucleotide improves liver function and inhibits liver carcinogenesis in vivo. Hepatology 59 (2014), 216–227.
12. Portnoy, V., Huang, V., Place, R.F., Li, L.C., Small RNA and transcriptional upregulation. Wiley Interdiscip. Rev. RNA 2 (2011), 748–760.
13. Portnoy, V., Lin, S.H., Li, K.H., Burlingame, A., Hu, Z.H., Li, H., Li, L.C., saRNA-guided Ago2 targets the RITA complex to promoters to stimulate transcription. Cell Res. 26 (2016), 320–335.
14. Perz, J.F., Armstrong, G.L., Farrington, L.A., Hutin, Y.J., Bell, B.P., The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J. Hepatol. 45 (2006), 529–538.
15. White, D.L., Kanwal, F., El-Serag, H.B., Association between nonalcoholic fatty liver disease and risk for hepatocellular cancer, based on systematic review. Clin. Gastroenterol. Hepatol. 10 (2012), 1342–1359.e2.
16. Johnson, P.J., Non-surgical treatment of hepatocellular carcinoma. HPB (Oxford) 7 (2005), 50–55.
17. Llovet, J.M., Ricci, S., Mazzaferro, V., Hilgard, P., Gane, E., Blanc, J.F., de Oliveira, A.C., Santoro, A., Raoul, J.L., Forner, A., et al., SHARP Investigators Study Group. Sorafenib in advanced hepatocellular carcinoma. N. Engl. J. Med. 359 (2008), 378–390.
18. Ramji, D.P., Foka, P., CCAAT/enhancer-binding proteins: structure, function and regulation. Biochem. J. 365 (2002), 561–575.
19. Akai, Y., Oitate, T., Koike, T., Shiojiri, N., Impaired hepatocyte maturation, abnormal expression of biliary transcription factors and liver fibrosis in C/EBPα(Cebpa)-knockout mice. Histol. Histopathol. 29 (2014), 107–125.
20. Flodby, P., Liao, D.Z., Blanck, A., Xanthopoulos, K.G., Hällström, I.P., Expression of the liver-enriched transcription factors C/EBP alpha, C/EBP beta, HNF-1, and HNF-4 in preneoplastic nodules and hepatocellular carcinoma in rat liver. Mol. Carcinog. 12 (1995), 103–109.
21. Tseng, H.H., Hwang, Y.H., Yeh, K.T., Chang, J.G., Chen, Y.L., Yu, H.S., Reduced expression of C/EBP alpha protein in hepatocellular carcinoma is associated with advanced tumor stage and shortened patient survival. J. Cancer Res. Clin. Oncol. 135 (2009), 241–247.
22. Johnson, P.J., Berhane, S., Kagebayashi, C., Satomura, S., Teng, M., Reeves, H.L., O'Beirne, J., Fox, R., Skowronska, A., Palmer, D., et al. Assessment of liver function in patients with hepatocellular carcinoma: a new evidence-based approach-the ALBI grade. J. Clin. Oncol. 33 (2015), 550–558.
23. Schuster, M.B., Porse, B.T., C/EBPalpha: a tumour suppressor in multiple tissues?. Biochim. Biophys. Acta 1766 (2006), 88–103.
24. Tan, E.H., Hooi, S.C., Laban, M., Wong, E., Ponniah, S., Wee, A., Wang, N.D., CCAAT/enhancer binding protein alpha knock-in mice exhibit early liver glycogen storage and reduced susceptibility to hepatocellular carcinoma. Cancer Res. 65 (2005), 10330–10337.
25. Ribero, D., Curley, S.A., Imamura, H., Madoff, D.C., Nagorney, D.M., Ng, K.K., Donadon, M., Vilgrain, V., Torzilli, G., Roh, M., et al. Selection for resection of hepatocellular carcinoma and surgical strategy: indications for resection, evaluation of liver function, portal vein embolization, and resection. Ann. Surg. Oncol. 15 (2008), 986–992.
26. ClinicalTrials.gov. (2016). First-in-human safety and tolerability study of MTL-CEBPA in patients with advanced liver cancer. https://ClinicalTrials.gov/show/NCT02716012.
27. Lima, W.F., Wu, H., Nichols, J.G., Sun, H., Murray, H.M., Crooke, S.T., Binding and cleavage specificities of human Argonaute2. J. Biol. Chem. 284 (2009), 26017–26028.
28. Elbashir, S.M., Martinez, J., Patkaniowska, A., Lendeckel, W., Tuschl, T., Functional anatomy of siRNAs for mediating efficient RNAi in Drosophila melanogaster embryo lysate. EMBO J. 20 (2001), 6877–6888.
29. Lundin, K.E., Gissberg, O., Smith, C.I., Oligonucleotide therapies: the past and the present. Hum. Gene Ther. 26 (2015), 475–485.
30. Khvorova, A., Reynolds, A., Jayasena, S.D., Functional siRNAs and miRNAs exhibit strand bias. Cell 115 (2003), 209–216.
31. Jaehning, J.A., The Paf1 complex: platform or player in RNA polymerase II transcription?. Biochim. Biophys. Acta 1799 (2010), 379–388.
32. Broering, R., Real, C.I., John, M.J., Jahn-Hofmann, K., Ickenstein, L.M., Kleinehr, K., Paul, A., Gibbert, K., Dittmer, U., Gerken, G., et al. Chemical modifications on siRNAs avoid Toll-like-receptor-mediated activation of the hepatic immune system in vivo and in vitro. Int. Immunol. 26 (2014), 35–46.
33. 4-induced liver failure in vivo. Hepatology 62:Suppl 1 (2015), 269A–270A.
34. Tolcher, A.W., Rodrigueza, W.V., Rasco, D.W., Patnaik, A., Papadopoulos, K.P., Amaya, A., Moore, T.D., Gaylor, S.K., Bisgaier, C.L., Sooch, M.P., et al. A phase 1 study of the BCL2-targeted deoxyribonucleic acid inhibitor (DNAi) PNT2258 in patients with advanced solid tumors. Cancer Chemother. Pharmacol. 73 (2014), 363–371.
35. Roberts, T.C., Hart, J.R., Kaikkonen, M.U., Weinberg, M.S., Vogt, P.K., Morris, K.V., Quantification of nascent transcription by bromouridine immunocapture nuclear run-on RT-qPCR. Nat. Protoc. 10 (2015), 1198–1211.